3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Urinary Bladder Neoplasms
2
Glioblastoma
2
Stomach Neoplasms
1
Solitary Pulmonary Nodule
1
Non-Muscle Invasive Bladder Neoplasms
1
Multiple Pulmonary Nodules
1
Medication Adherence
1
Margins of Excision
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Glioma
1
Esophageal Neoplasms
1
Early-stage Peripheral Non-small Cell Lung Cancer
1
Dementia
1
Cognitive Dysfunction
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Alzheimer Disease
1
Interventions
pembrolizumab
12
Pemetrexed
9
Cisplatin
9
Nivolumab
8
Carboplatin
8
Ipilimumab
7
Cyclophosphamide
6
fludarabine
5
durvalumab
4
tremelimumab
2
Radiotherapy, Intensity-Modulated
2
Gemcitabine
2
Cerebral Decortication
2
tocilizumab
1
tislelizumab
1
tazemetostat
1
sotorasib
1
ruxolitinib
1
osimertinib
1
olaparib
1
obinutuzumab
1
naptumomab estafenatox
1
fludarabine phosphate
1
decitabine and cedazuridine drug combination
1
bintrafusp alfa protein, human
1
avelumab
1
atezolizumab
1
Tumor Burden
1
Tablets
1
Saline Solution
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Mesothelioma
×
Drug Delivery Systems
×
1 year
×
Clear all
No trials found.